MeSH term
Frequency | Condition_Probility | Humans | 398 | 0.0 |
Mice | 7 | 0.0 |
Neoplasms/*radionuclide imaging | 2 | 33.0 |
Research Support, U.S. Gov't, P.H.S. | 37 | 0.0 |
Spleen/radionuclide imaging | 2 | 33.0 |
Tissue Distribution | 4 | 0.0 |
Risk Factors | 3 | 0.0 |
Attitude of Health Personnel | 2 | 6.0 |
Attitude to Health | 2 | 4.0 |
Health Knowledge, Attitudes, Practice | 2 | 6.0 |
Physician-Patient Relations | 2 | 7.0 |
United States | 31 | 3.0 |
Child | 53 | 0.0 |
Follow-Up Studies | 18 | 0.0 |
Male | 192 | 0.0 |
Patient Care Planning | 2 | 13.0 |
Aged | 83 | 0.0 |
Efficiency, Organizational | 2 | 40.0 |
Comparative Study | 45 | 0.0 |
Female | 207 | 0.0 |
Middle Aged | 112 | 0.0 |
Prospective Studies | 11 | 0.0 |
Adult | 147 | 0.0 |
Double-Blind Method | 9 | 0.0 |
Ophthalmic Solutions | 3 | 14.0 |
Diagnosis, Differential | 10 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Multiple Endocrine Neoplasia Type 1/*genetics | 2 | 1.0 |
Pedigree | 7 | 0.0 |
Research Support, Non-U.S. Gov't | 71 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
*Chromosomes, Human, Pair 11 | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 18 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Ethics, Medical | 2 | 11.0 |
Interpersonal Relations | 6 | 26.0 |
*Truth Disclosure | 2 | 20.0 |
Evaluation Studies | 7 | 1.0 |
Patient Care Team | 2 | 11.0 |
Base Sequence | 8 | 0.0 |
Cell Line | 8 | 0.0 |
Kinetics | 15 | 0.0 |
Microscopy, Electron | 4 | 0.0 |
Molecular Sequence Data | 4 | 0.0 |
Nursing Assessment | 2 | 33.0 |
Laminectomy | 2 | 22.0 |
Acute Disease | 6 | 0.0 |
Chromosome Disorders | 2 | 0.0 |
*Referral and Consultation | 2 | 40.0 |
Brazil | 3 | 1.0 |
English Abstract | 45 | 0.0 |
DNA/genetics | 3 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Exons | 2 | 0.0 |
Introns | 2 | 0.0 |
Drug Interactions | 3 | 0.0 |
Drug Therapy, Combination | 5 | 0.0 |
Infant, Newborn | 19 | 0.0 |
Questionnaires | 4 | 0.0 |
Infant | 25 | 0.0 |
Adolescent | 70 | 0.0 |
Cornea/*surgery | 2 | 28.0 |
Myopia/physiopathology/*surgery | 2 | 66.0 |
Injections | 2 | 1.0 |
Emotions | 2 | 9.0 |
Age Factors | 16 | 0.0 |
Child, Preschool | 31 | 0.0 |
Electrocardiography | 4 | 1.0 |
Prognosis | 9 | 0.0 |
*Adaptation, Psychological | 2 | 6.0 |
Animals | 29 | 0.0 |
*Self Concept | 2 | 11.0 |
Methods | 8 | 3.0 |
Hand/blood supply | 2 | 22.0 |
Protein Binding | 8 | 0.0 |
Reference Values | 2 | 0.0 |
*Respiration | 2 | 5.0 |
Time Factors | 32 | 0.0 |
Risk | 15 | 1.0 |
Psychotherapy | 3 | 25.0 |
Child Development | 3 | 15.0 |
Probability | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Recurrence | 3 | 0.0 |
Intermittent Claudication/diagnosis | 2 | 100.0 |
Pressure | 3 | 2.0 |
Rabbits | 3 | 0.0 |
Patient Readmission | 2 | 66.0 |
Internship and Residency | 2 | 40.0 |
Molecular Weight | 2 | 0.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Rats | 13 | 0.0 |
Vasoactive Intestinal Peptide/*genetics | 3 | 15.0 |
Attitude | 7 | 23.0 |
Myelography | 3 | 50.0 |
Tomography, X-Ray Computed | 8 | 1.0 |
Eye Diseases/pathology | 2 | 50.0 |
Aged, 80 and over | 2 | 0.0 |
Enema | 2 | 22.0 |
Premedication | 2 | 10.0 |
Random Allocation | 8 | 1.0 |
Catalase/blood | 2 | 9.0 |
Glutathione Peroxidase/blood | 2 | 5.0 |
Lipid Peroxides/*blood | 3 | 17.0 |
Vitamin E/*blood | 3 | 13.0 |
Sex Factors | 7 | 0.0 |
Coitus | 2 | 11.0 |
False Negative Reactions | 5 | 3.0 |
Pregnancy | 28 | 0.0 |
*Tomography, X-Ray Computed | 4 | 4.0 |
Retrospective Studies | 9 | 0.0 |
*Coronary Artery Bypass | 3 | 4.0 |
*Vascular Patency | 2 | 50.0 |
Streptococcus pyogenes/isolation & purification | 2 | 66.0 |
Visual Acuity | 7 | 4.0 |
Administration, Oral | 8 | 0.0 |
Injections, Intravenous | 7 | 1.0 |
Myocardium/metabolism | 2 | 0.0 |
Mucus/*metabolism | 2 | 28.0 |
Cell Division | 2 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Breast Neoplasms/*epidemiology | 2 | 18.0 |
Democratic Republic of the Congo | 2 | 14.0 |
Arrhythmia/*drug therapy | 4 | 36.0 |
Biopsy | 2 | 0.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Infusions, Parenteral | 4 | 2.0 |
Liver/pathology | 3 | 1.0 |
Birth Weight | 2 | 1.0 |
Antigens, Viral/*analysis | 2 | 4.0 |
Chronic Disease | 4 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Genes | 2 | 0.0 |
Vasoactive Intestinal Peptide/biosynthesis/*genetics | 2 | 100.0 |
Epithelial Cells | 2 | 0.0 |
Histocytochemistry | 2 | 0.0 |
Syndrome | 6 | 0.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Binding, Competitive | 2 | 0.0 |
In Vitro | 5 | 0.0 |
Heart Atria | 2 | 6.0 |
*Fertilization in Vitro | 2 | 1.0 |
*Pregnancy | 2 | 1.0 |
Anti-Bacterial Agents/therapeutic use | 3 | 2.0 |
Diagnostic Errors | 2 | 2.0 |
Patch Tests | 3 | 9.0 |
Erythrocytes/metabolism | 2 | 1.0 |
Cell Differentiation | 3 | 0.0 |
Socioeconomic Factors | 2 | 1.0 |
Antibodies, Bacterial/analysis | 3 | 8.0 |
False Positive Reactions | 5 | 2.0 |
Species Specificity | 3 | 0.0 |
Biological Availability | 2 | 0.0 |
Phagocytosis | 2 | 0.0 |
Echocardiography | 2 | 0.0 |
*Child Abuse | 8 | 100.0 |
Psychological Tests | 2 | 5.0 |
Eye Diseases/*complications | 2 | 50.0 |
Intraocular Pressure/drug effects | 2 | 25.0 |
Lasers/*therapeutic use | 4 | 30.0 |
Ophthalmoscopy | 2 | 8.0 |
Cognition | 2 | 3.0 |
Growth | 3 | 6.0 |
Intelligence Tests | 2 | 3.0 |
Mother-Child Relations | 3 | 60.0 |
Personality Tests | 3 | 15.0 |
Child Behavior | 3 | 42.0 |
Mothers/*psychology | 4 | 44.0 |
Parent-Child Relations | 3 | 30.0 |
Personality Assessment | 2 | 15.0 |
Self Concept | 3 | 12.0 |
Social Class | 4 | 10.0 |
Aging | 3 | 0.0 |
Behavior Therapy | 2 | 13.0 |
Preoperative Care | 2 | 1.0 |
Professional-Family Relations | 2 | 66.0 |
Mucus/*physiology | 3 | 75.0 |
Technetium/diagnostic use | 2 | 7.0 |
Trachea/*physiology | 2 | 33.0 |
Child Behavior Disorders/etiology | 2 | 100.0 |
Intelligence | 3 | 9.0 |
Language Development | 2 | 50.0 |
Clinical Trials | 6 | 0.0 |
Failure to Thrive/*psychology | 2 | 100.0 |
Child Rearing | 3 | 75.0 |
Labor, Obstetric | 2 | 4.0 |
Maternal Age | 2 | 2.0 |
Environmental Exposure | 2 | 1.0 |
Administration, Topical | 2 | 1.0 |
Blood Pressure/drug effects | 3 | 0.0 |
Drug Evaluation | 2 | 0.0 |
Heart Rate/drug effects | 4 | 1.0 |
Constriction, Pathologic | 2 | 8.0 |
Parents/*psychology | 2 | 22.0 |
Statistics | 2 | 0.0 |
Contraception Behavior | 2 | 50.0 |
Family Characteristics | 2 | 12.0 |
Great Britain | 3 | 1.0 |
Hospitalization | 4 | 3.0 |
Radioimmunoassay | 3 | 0.0 |
Skin/pathology | 2 | 0.0 |
Intraocular Pressure | 3 | 11.0 |
Body Weight | 3 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Chromatography, DEAE-Cellulose | 2 | 3.0 |
Amiodarone/metabolism | 2 | 100.0 |
Anilides/metabolism | 2 | 66.0 |
Anti-Arrhythmia Agents/*metabolism | 3 | 60.0 |
*Benzeneacetamides | 3 | 37.0 |
Disopyramide/metabolism | 2 | 100.0 |
Encainide | 3 | 100.0 |
Lidocaine/metabolism | 3 | 60.0 |
Piperidines/metabolism | 2 | 25.0 |
Procainamide/metabolism | 2 | 100.0 |
Quinidine/metabolism | 2 | 28.0 |
*Aging | 4 | 2.0 |
Amino Acids/metabolism | 2 | 2.0 |
Carbohydrates/metabolism | 2 | 3.0 |
Dietary Fats/metabolism | 2 | 6.0 |
*Digestive Physiology | 2 | 6.0 |
Digestive System/anatomy & histology | 2 | 66.0 |
Disaccharidases/metabolism | 2 | 50.0 |
Electrolytes/metabolism | 2 | 11.0 |
Intestinal Absorption | 3 | 2.0 |
Vitamins/metabolism | 2 | 50.0 |
Australia | 2 | 1.0 |
Urban Population | 2 | 1.0 |
*Models, Biological | 2 | 1.0 |
Postoperative Complications | 8 | 5.0 |
Heart/drug effects | 2 | 4.0 |
*Pregnancy in Adolescence | 2 | 50.0 |
Hip Joint | 2 | 50.0 |
Hemodynamic Processes/*drug effects | 4 | 3.0 |
Fluorescein Angiography | 4 | 3.0 |
*Ultrasonography | 2 | 6.0 |
Chemistry | 2 | 0.0 |
Half-Life | 3 | 0.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Minnesota | 2 | 9.0 |
Blood Proteins/*metabolism | 3 | 1.0 |
Continental Population Groups | 2 | 1.0 |
Biological Transport | 2 | 0.0 |
Abortion, Induced/*methods | 2 | 25.0 |
Centers for Disease Control and Prevention (U.S.) | 2 | 8.0 |
Pregnancy Trimester, Second | 4 | 1.0 |
Abortion, Legal/*mortality | 3 | 100.0 |
*Maternal Mortality | 2 | 66.0 |
Pregnancy Trimester, First | 2 | 0.0 |
Hospitals | 2 | 22.0 |
Binding Sites, Antibody | 2 | 0.0 |
Bilirubin/blood | 2 | 2.0 |
Serum Albumin/metabolism | 2 | 1.0 |
Aerosols | 2 | 2.0 |
Angiography | 3 | 7.0 |
Technetium | 2 | 33.0 |
Temperature | 4 | 0.0 |
Gestational Age | 4 | 0.0 |
Pregnancy Trimester, Third | 2 | 1.0 |
Arnold-Chiari Malformation/*surgery | 3 | 100.0 |
Dura Mater/surgery | 2 | 100.0 |
Platybasia/*surgery | 3 | 100.0 |
Posture | 4 | 4.0 |
Craniotomy | 2 | 15.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Models, Biological | 3 | 0.0 |
Placebos | 4 | 1.0 |
Tritium | 2 | 0.0 |
*Chromosome Aberrations | 2 | 0.0 |
*Light Coagulation | 2 | 100.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Medulla Oblongata/physiopathology | 2 | 100.0 |
Skull/*abnormalities | 2 | 10.0 |
Spinal Cord Compression/*surgery | 2 | 100.0 |
Drainage | 2 | 10.0 |
Gallium Radioisotopes/*diagnostic use | 3 | 27.0 |
Consanguinity | 2 | 0.0 |
Cell Survival | 2 | 0.0 |
Transplantation, Autologous | 2 | 0.0 |
Disease Outbreaks/*epidemiology | 2 | 66.0 |
Epidemiologic Methods | 2 | 3.0 |
Cross Reactions | 2 | 0.0 |
Diuretics/therapeutic use | 2 | 3.0 |
Lumbar Vertebrae/radiography | 2 | 28.0 |
Nephrectomy | 2 | 2.0 |
Renin/blood | 6 | 1.0 |
Sodium/urine | 2 | 3.0 |
Blood Proteins/metabolism | 2 | 0.0 |
Abortion, Criminal | 2 | 100.0 |
Eye Diseases/surgery | 2 | 100.0 |
Blood Pressure/*drug effects | 2 | 1.0 |
Substance Withdrawal Syndrome/*physiopathology | 3 | 60.0 |
Abortifacient Agents/*adverse effects | 2 | 100.0 |
Abortion, Induced/*mortality | 2 | 100.0 |
Prostaglandins F/*adverse effects | 2 | 100.0 |
Immunoglobulin M/*biosynthesis | 2 | 10.0 |
Menopause | 2 | 0.0 |
New York | 2 | 9.0 |
*Students, Medical | 2 | 5.0 |
Ganglionic Blockers/pharmacology | 2 | 50.0 |
Abortion, Spontaneous/*mortality | 2 | 100.0 |
Medical Records | 2 | 2.0 |
Neoplasm Metastasis | 2 | 0.0 |
*Antibody Formation | 2 | 2.0 |
Immunologic Memory | 2 | 0.0 |
Germany, West | 2 | 4.0 |
Substance-Related Disorders/*complications | 2 | 15.0 |
Chromatography, Gas | 2 | 2.0 |
Adsorption | 2 | 1.0 |
*Lymphocyte Activation | 2 | 0.0 |
African Continental Ancestry Group | 2 | 0.0 |
European Continental Ancestry Group | 2 | 0.0 |
*Sunlight | 2 | 14.0 |
*African Americans | 2 | 9.0 |
Prejudice | 2 | 13.0 |
Social Adjustment | 2 | 20.0 |
Dermatoglyphics | 2 | 16.0 |
Schizophrenia/*drug therapy | 2 | 6.0 |
Drug Combinations | 2 | 0.0 |
